Biologic nanoparticles and platelet reactivity

Virginia M Miller, Larry W. Hunter, Kevin Chu, Vivasvat Kaul, Phillip D. Squillace, John C Lieske, Muthuvel Jayachandran

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Aim: Nanosized particles (NPs) enriched in hydroxyapatite and protein isolated from calcified human tissue accelerate occlusion of endothelium-denuded arteries when injected intravenously into rabbits. Since platelet aggregation and secretory processes participate in normal hemostasis, thrombosis and vascular remodeling, experiments were designed to determine if these biologic NPs alter specific platelet functions in vitro. Methods: Platelet-rich plasma was prepared from citrate anticoagulated human blood. Platelet aggregation and ATP secretion were monitored in response to thrombin receptor agonists peptide (10 μM) or convulxin (50 μg/ml) prior to and following 15 min incubation with either control solution, humanderived NPs, bovine-derived NPs or crystals of hydroxyapatite at concentrations of 50 and 150 nephelometric turbidity units. Results: Incubation of platelets for 15 min with either human- or bovine-derived NPs reduced aggregation induced by thrombin receptor activator peptide and convulxin in a concentration-dependent manner. Hydroxyapatite caused a greater inhibition than either of the biologically derived NPs. Human-derived NPs increased ATP secretion by unstimulated platelets during the 15 min incubation period. Conclusion: Effects of bovine-derived and hydroxyapatite NPs on basal release of ATP were both time and concentration dependent. These results suggest that biologic NPs modulate both platelet aggregation and secretion. Biologically derived NPs could modify platelet responses within the vasculature, thereby reducing blood coagulability and the vascular response to injury.

Original languageEnglish (US)
Pages (from-to)725-733
Number of pages9
JournalNanomedicine
Volume4
Issue number7
DOIs
StatePublished - Oct 2009

Fingerprint

Durapatite
Platelets
aggregation
Nanoparticles
Blood Platelets
Platelet Aggregation
Thrombin Receptors
Adenosine Triphosphate
Hydroxyapatite
Adenosinetriphosphate
Agglomeration
Platelet-Rich Plasma
secretion
Secretory Pathway
Hemostasis
Citric Acid
Peptides
incubation
Endothelium
Blood Vessels

Keywords

  • ATP secretion
  • Calcium phosphate
  • Dense granules
  • Fetuin
  • Platelet aggregation
  • Protein/mineral complexes
  • Thrombin

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Development

Cite this

Miller, V. M., Hunter, L. W., Chu, K., Kaul, V., Squillace, P. D., Lieske, J. C., & Jayachandran, M. (2009). Biologic nanoparticles and platelet reactivity. Nanomedicine, 4(7), 725-733. https://doi.org/10.2217/nnm.09.61

Biologic nanoparticles and platelet reactivity. / Miller, Virginia M; Hunter, Larry W.; Chu, Kevin; Kaul, Vivasvat; Squillace, Phillip D.; Lieske, John C; Jayachandran, Muthuvel.

In: Nanomedicine, Vol. 4, No. 7, 10.2009, p. 725-733.

Research output: Contribution to journalArticle

Miller, VM, Hunter, LW, Chu, K, Kaul, V, Squillace, PD, Lieske, JC & Jayachandran, M 2009, 'Biologic nanoparticles and platelet reactivity', Nanomedicine, vol. 4, no. 7, pp. 725-733. https://doi.org/10.2217/nnm.09.61
Miller VM, Hunter LW, Chu K, Kaul V, Squillace PD, Lieske JC et al. Biologic nanoparticles and platelet reactivity. Nanomedicine. 2009 Oct;4(7):725-733. https://doi.org/10.2217/nnm.09.61
Miller, Virginia M ; Hunter, Larry W. ; Chu, Kevin ; Kaul, Vivasvat ; Squillace, Phillip D. ; Lieske, John C ; Jayachandran, Muthuvel. / Biologic nanoparticles and platelet reactivity. In: Nanomedicine. 2009 ; Vol. 4, No. 7. pp. 725-733.
@article{cc8eb320efc341418a384d15b77c54bb,
title = "Biologic nanoparticles and platelet reactivity",
abstract = "Aim: Nanosized particles (NPs) enriched in hydroxyapatite and protein isolated from calcified human tissue accelerate occlusion of endothelium-denuded arteries when injected intravenously into rabbits. Since platelet aggregation and secretory processes participate in normal hemostasis, thrombosis and vascular remodeling, experiments were designed to determine if these biologic NPs alter specific platelet functions in vitro. Methods: Platelet-rich plasma was prepared from citrate anticoagulated human blood. Platelet aggregation and ATP secretion were monitored in response to thrombin receptor agonists peptide (10 μM) or convulxin (50 μg/ml) prior to and following 15 min incubation with either control solution, humanderived NPs, bovine-derived NPs or crystals of hydroxyapatite at concentrations of 50 and 150 nephelometric turbidity units. Results: Incubation of platelets for 15 min with either human- or bovine-derived NPs reduced aggregation induced by thrombin receptor activator peptide and convulxin in a concentration-dependent manner. Hydroxyapatite caused a greater inhibition than either of the biologically derived NPs. Human-derived NPs increased ATP secretion by unstimulated platelets during the 15 min incubation period. Conclusion: Effects of bovine-derived and hydroxyapatite NPs on basal release of ATP were both time and concentration dependent. These results suggest that biologic NPs modulate both platelet aggregation and secretion. Biologically derived NPs could modify platelet responses within the vasculature, thereby reducing blood coagulability and the vascular response to injury.",
keywords = "ATP secretion, Calcium phosphate, Dense granules, Fetuin, Platelet aggregation, Protein/mineral complexes, Thrombin",
author = "Miller, {Virginia M} and Hunter, {Larry W.} and Kevin Chu and Vivasvat Kaul and Squillace, {Phillip D.} and Lieske, {John C} and Muthuvel Jayachandran",
year = "2009",
month = "10",
doi = "10.2217/nnm.09.61",
language = "English (US)",
volume = "4",
pages = "725--733",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "7",

}

TY - JOUR

T1 - Biologic nanoparticles and platelet reactivity

AU - Miller, Virginia M

AU - Hunter, Larry W.

AU - Chu, Kevin

AU - Kaul, Vivasvat

AU - Squillace, Phillip D.

AU - Lieske, John C

AU - Jayachandran, Muthuvel

PY - 2009/10

Y1 - 2009/10

N2 - Aim: Nanosized particles (NPs) enriched in hydroxyapatite and protein isolated from calcified human tissue accelerate occlusion of endothelium-denuded arteries when injected intravenously into rabbits. Since platelet aggregation and secretory processes participate in normal hemostasis, thrombosis and vascular remodeling, experiments were designed to determine if these biologic NPs alter specific platelet functions in vitro. Methods: Platelet-rich plasma was prepared from citrate anticoagulated human blood. Platelet aggregation and ATP secretion were monitored in response to thrombin receptor agonists peptide (10 μM) or convulxin (50 μg/ml) prior to and following 15 min incubation with either control solution, humanderived NPs, bovine-derived NPs or crystals of hydroxyapatite at concentrations of 50 and 150 nephelometric turbidity units. Results: Incubation of platelets for 15 min with either human- or bovine-derived NPs reduced aggregation induced by thrombin receptor activator peptide and convulxin in a concentration-dependent manner. Hydroxyapatite caused a greater inhibition than either of the biologically derived NPs. Human-derived NPs increased ATP secretion by unstimulated platelets during the 15 min incubation period. Conclusion: Effects of bovine-derived and hydroxyapatite NPs on basal release of ATP were both time and concentration dependent. These results suggest that biologic NPs modulate both platelet aggregation and secretion. Biologically derived NPs could modify platelet responses within the vasculature, thereby reducing blood coagulability and the vascular response to injury.

AB - Aim: Nanosized particles (NPs) enriched in hydroxyapatite and protein isolated from calcified human tissue accelerate occlusion of endothelium-denuded arteries when injected intravenously into rabbits. Since platelet aggregation and secretory processes participate in normal hemostasis, thrombosis and vascular remodeling, experiments were designed to determine if these biologic NPs alter specific platelet functions in vitro. Methods: Platelet-rich plasma was prepared from citrate anticoagulated human blood. Platelet aggregation and ATP secretion were monitored in response to thrombin receptor agonists peptide (10 μM) or convulxin (50 μg/ml) prior to and following 15 min incubation with either control solution, humanderived NPs, bovine-derived NPs or crystals of hydroxyapatite at concentrations of 50 and 150 nephelometric turbidity units. Results: Incubation of platelets for 15 min with either human- or bovine-derived NPs reduced aggregation induced by thrombin receptor activator peptide and convulxin in a concentration-dependent manner. Hydroxyapatite caused a greater inhibition than either of the biologically derived NPs. Human-derived NPs increased ATP secretion by unstimulated platelets during the 15 min incubation period. Conclusion: Effects of bovine-derived and hydroxyapatite NPs on basal release of ATP were both time and concentration dependent. These results suggest that biologic NPs modulate both platelet aggregation and secretion. Biologically derived NPs could modify platelet responses within the vasculature, thereby reducing blood coagulability and the vascular response to injury.

KW - ATP secretion

KW - Calcium phosphate

KW - Dense granules

KW - Fetuin

KW - Platelet aggregation

KW - Protein/mineral complexes

KW - Thrombin

UR - http://www.scopus.com/inward/record.url?scp=73349115751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349115751&partnerID=8YFLogxK

U2 - 10.2217/nnm.09.61

DO - 10.2217/nnm.09.61

M3 - Article

VL - 4

SP - 725

EP - 733

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 7

ER -